Efficacy, Tolerability, and Acceptance of Long-Lasting Antipsychotics in Children and Adolescents: A Systematic Review

Benarous, Xavier; Cottin, Guillaume; Lahaye, Hélène; Rivière, Sébastien; Guilé, Jean-Marc; Speranza, Mario; Bonnot, Olivier; Cohen, David

doi:10.1089/cap.2021.0124

Cited by 7 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies have indicated that while antipsychotic drugs block the antipsychotic effect of dopamine in the limbic system of the midbrain, they also antagonize D2 receptors in the tuberoinfundibular pathway, leading to hyperprolactinemia. [ 30 ] This suggests that Xiaoyao Pill may potentially inhibit the antagonistic effect of antipsychotic drugs on D2 receptors, thereby reducing prolactin production. The present study results further support the high efficacy of combining Xiaoyao Pill with Western medicine in the treatment of schizophrenia.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of Xiaoyao Pill combined with Western medicine in the treatment of schizophrenia: A Meta-analysis and Systematic review

Cai,

Liu,

Jiang

et al. 2024

Medicine

View full text Add to dashboard Cite

Background: The efficacy and safety of Xiaoyao Pill combined with Western medicine in the treatment of schizophrenia are still inconclusive. This meta-analysis summarized relevant studies to compare the efficacy and safety of Xiaoyao Pill combined with Western medicine and Western medicine alone in the treatment of schizophrenia, aiming to provide guidance for clinical treatment. Methods: In this meta-analysis, we searched PubMed, Embase, Cochrane Library, CNKI, Wanfang, CQVIP, and CBM databases from the establishment of the databases to August 2023. The study proposed to include studies that reported combination of Xiaoyao Pill with Western medicine and Western medicine alone in the treatment of schizophrenia, excluding published literature, unpublished literature, literature with incomplete or inadequate information, animal experiments, literature reviews and systematic studies. Data were analyzed using Review manager 5.3. Results: About 9 studies (6 RCTs and 3 case–control studies) were included in this meta-analysis. The sample size ranged from 60 to 128, with a total of 779 patients, including 395 in the combined treatment group and 384 in the control group. Pooled results showed that the total effective rate of combined treatment group was significantly higher than that of Western medicine alone (OR = 4.21, 95% CI: 1.50–11.83, P = .006). Positive and Negative Syndrome Scale (PANSS) (−) (MD = −2.30, 95% CI: −3.72 ~ −0.89, P = .001) and PANSS (+) (MD = −2.60, 95% CI: −3.34 ~ −1.86, P < .00001) of combined treatment group were all significantly lower than that of Western medicine alone. Additionally, PRL levels of combined treatment group was significantly lower than that of Western medicine alone (MD = −28.78, 95% CI: −42.20 ~ −15.35, P < .0001). However, there was no significant difference in BPRS and total PANSS between combined treatment group and Western medicine alone group. Notably, pooled results showed that there was no significant difference in incidence of adverse events between combined treatment group and Western medicine alone group. Conclusion: The effective rate of Xiaoyao Pill combined with Western medicine in the treatment of schizophrenia is higher than that of Western medicine alone, which can effectively relieve the positive and negative symptoms of schizophrenia, and can significantly reduce the level of PRL. In the treatment of schizophrenia, clinicians can give priority to Xiaoyao Pill combined with Western medicine therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of Xiaoyao Pill combined with Western medicine in the treatment of schizophrenia: A Meta-analysis and Systematic review

Cai,

Liu,

Jiang

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…Si bien no existe ninguna formulación de depósito aprobada por las agencias reguladoras en pediatría, en el año 2013 la Asociación Americana de Psiquiatría del Niño y del Adolescente recomendó el uso off label de este grupo de fármacos en pacientes no adherentes al tratamiento a partir de los 15 años con la finalidad de prevenir la transición a fases avanzadas del trastorno. Sin embargo, la evidencia en cuanto a su eficacia y seguridad es escasa (Benarous, 2022).…”

Section: Manejo Del Tratamiento Psicofarmacológicounclassified

Tratamiento psicofarmacológico de la esquizofrenia en la población infantojuvenil: estado del arte

Iveli

2024

Vertex Rev Arg Psiquiatr

View full text Add to dashboard Cite

La esquizofrenia es una patología crónica y grave que se caracteriza por la presencia de delirios, alucinaciones, síntomas negativos, desorganización del pensamiento y del comportamiento. Si bien su prevalencia en menores de 13 años es muy baja, aumenta sustancialmente durante la adolescencia. Cuando se desarrolla antes de los 18 años se denomina esquizofrenia de inicio precoz y representa del 12 al 33 % del total de los individuos con este trastorno. Existen fármacos como el haloperidol, risperidona, paliperidona, aripiprazol, olanzapina, quetiapina, brexpiprazol y lurasidona aprobados por la Food and Drug Administration (FDA) para el tratamiento de la esquizofrenia en adolescentes. Sin embargo, a excepción del haloperidol, todas las indicaciones farmacológicas que se realizan para tratar este trastorno en menores de 13 años resultan “off label” (fuera de las indicaciones de la ficha técnica). Si bien esta práctica no se encuentra prohibida, conlleva riesgos adicionales. En el siguiente trabajo se revisará la evidencia disponible acerca del uso de los antipsicóticos para el tratamiento de la esquizofrenia en la población infantojuvenil, con el objetivo de realizar una síntesis de la información con aplicabilidad clínica.

show abstract

Trends in the use of long-acting injectable antipsychotics in children and adolescents in France between 2014 and 2018

Benarous

Lahaye

Cottin

et al. 2022

Schizophrenia Research

View full text Add to dashboard Cite

Efficacy, Tolerability, and Acceptance of Long-Lasting Antipsychotics in Children and Adolescents: A Systematic Review

Cited by 7 publications

References 56 publications

Efficacy and safety of Xiaoyao Pill combined with Western medicine in the treatment of schizophrenia: A Meta-analysis and Systematic review

Efficacy and safety of Xiaoyao Pill combined with Western medicine in the treatment of schizophrenia: A Meta-analysis and Systematic review

Tratamiento psicofarmacológico de la esquizofrenia en la población infantojuvenil: estado del arte

Trends in the use of long-acting injectable antipsychotics in children and adolescents in France between 2014 and 2018

Contact Info

Product

Resources

About